Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
 'Motexafin Gadolinium' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Motexafin Gadolinium' found in 1 term [] and 1 definition []
1 - 2 (of 2)     
Result Pages : [1]
Searchterm 'Motexafin Gadolinium' was also found in the following services: 
spacer
News  (2)  Resources  (1)  
 
Motexafin GadoliniumInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
An agent currently in Phase III clinical trials that selectively targets diseased cells because they have increased rates of metabolism. Once inside the diseased cell, motexafin gadolinium may work to disrupt its energy production and the ability to repair itself. This biolocalization can be confirmed because the compound can be seen via MRI. Motexafin gadolinium accumulates in diseased cells with repeat doses and remains in the cells for days.
Motexafin gadolinium is being investigated in clinical trials, in combination chemotherapy and with radiation therapy for the treatment of several types of cancer.
spacer
 
• Share the entry 'Motexafin Gadolinium':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'Motexafin Gadolinium' (2).Open this link in a new window.
 
Further Reading:
  News & More:
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Friday, 21 December 2007   by www.prnewswire.com    
MRI Resources 
Manufacturers - Most Wanted - Pediatric and Fetal MRI - Stent - Libraries - Liver Imaging
 
Pharmacyclics, Inc.MRI Resource Directory:
 - Manufacturers -
 
www.pcyc.com Pharmacyclics is a pharmaceutical company developing novel agents to improve current therapeutic approaches to cancer, cardiovascular diseases, and inflammation. The company's proprietary products are derived from its core technology in biometallic chemistry. These products under development are based upon small molecules, which bind metals in a unique way and are capable of capturing and focusing forms of energy used in a variety of medical applications. The company has one product in registration with the FDA, Gadolite® Oral Suspension, a contrast agent for imaging the gastrointestinal tract; two products in clinical development, Gd-Tex (Motexafin gadolinium), a radiation sensitizer, Lu-Tex, a photosensitizer; and several compounds in preclinical development.

Product Information
TRADE NAME
(LOCAL DISTRIBUTION)
FOR SALE FOR SALE /
DEVELOPMENT
DEVELOPMENT
Gadolite® Oral Suspension
Motexafin Gadolinium

Contact Information
MAIL Pharmacyclics Inc.
995 East Arques Avenue
94085 Sunnyvale, California
USA
PHONE +1-408-774-0330
FAX +1-408-774-0340
E-MAIL info@pcyc.com
ONLINE www.pcyc.com
spacer

• View the DATABASE results for 'Pharmacyclics, Inc.' (2).Open this link in a new window


• View the NEWS results for 'Pharmacyclics, Inc.' (5).Open this link in a new window.
 
Further Reading:
  News & More:
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Friday, 21 December 2007   by www.prnewswire.com    
Texaphyrin Compounds Visualize Vulnerable Plaque
Friday, 4 June 2004   by www.hospimedica.com    
MRI Resources 
Blood Flow Imaging - Homepages - Pediatric and Fetal MRI - Resources - Spine MRI - Distributors
 
     1 - 2 (of 2)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



In 2075 (after about 100 years of ...) the MRI scan will be :
obsolete 
done with handheld probe 
done at home (app, ...) 
a 3 second walk through 
daily done 
replaced by something much ... 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • 
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 18 March 2019]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]